The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Re: Ipi Success Stories and/or Thoughts

Forums General Melanoma Community Ipi Success Stories and/or Thoughts Re: Ipi Success Stories and/or Thoughts


      Hi Sharon

      Thanks for posing this question. I too will be most curious as to opinions. I had hoped to do B-RAF trial here about two months ago but proved to be negative.  I am now on temodar (stage IV drug) first round and if I show progression will be going on to the compassionate ipi trial, considering the continued growth of my tumors probably heading in that direction. I thought I would try B-RAF first since ‘ipi’ could be my back-up plan…but that didn’t work out.  Anyways the problem with the brain barrier would have made me re-think if I was going forward now with B-RAF.

      Unfortunately, the timing of the new bulletin board with not all on board yet could slow down the responses.  Val

    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.